​​​Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool. 

Publication & Editorial Staff Contacts

Publication Phil Daly Phil.Daly@wolterskluwer.com Production Editor Asha Ladwa Asha.Ladwa@​wolterskluwer.com ​​Marketing Danielle Beren Danielle.Beren@wolterskluwer.com Translation, Rights & Licensing translationrights@wolterskluwer.com  healthlicensing@wolterskluwer.com​ Special Projects and Reprints (U.S./Canada) Alan Moore Alan.Moore@wolterskluwer.com Reprints (non-U.S./Canada)​ ​internationalreprints@wolterskluwer.com​ Supplements Phil Daly, Senior Publisher Phone: +44 (0)203 197 6676 Phil.Daly@wolterskluwer.com​ ​International Advertising Representative Avia Potashnik Advertising & Sponsorship Manager, Europe Phone: +44 203 197 6722 E-mail: avia.potashnik@wolterskluwer.com LWW Business Offices Citi Building, 41st Floor 25 Canada Square Canary Wharf London E14 5LQ, UK Phone: +44(0)20 3197 6500 www.lww.com

Editor-in-Chief Mels Sluyser, PhD The Netherlands Cancer Institute-H4 Plesmanlaan 121 1066 CX Amsterdam The Netherlands Phone: +31 35 52 59 943 Fax: +31 20 51 22 029 m.sluyser@planet.nl